Rigor and Reproducibility for Biomarkers in Type 1 Diabetes Clinical Research
This grant supports a consortium to rigorously identify, validate, and standardize biomarkers for better prevention, diagnosis, and management of Type 1 Diabetes.
Funder: National Institutes of Health
Due Dates (Anticipated): June 2026 (Full application deadline, projected)
Funding Amounts: Estimated total program funding: $5,200,000; ~8 awards expected; individual award size not specified.
Summary: Supports a consortium to systematically identify, rigorously evaluate, validate, and harmonize biomarkers critical for the prevention, diagnosis, and clinical management of Type 1 Diabetes.
Key Information: This is a forecasted opportunity; all deadlines are projected and may change.
Description
This initiative aims to establish a research consortium focused on advancing the identification, rigorous evaluation, validation, and harmonization of biomarkers essential to the prevention, diagnosis, and clinical management of Type 1 Diabetes (T1D). Despite advances in T1D research, there is a critical need for reliable and reproducible biomarkers that reflect the complexity of autoimmune processes, metabolic dysregulation, and individual patient variability.
The consortium will leverage state-of-the-art methodologies—including clinical chemistry, genomics, proteomics, metabolomics, immunophenotyping, and imaging—alongside longitudinal patient cohorts and electronic health record (EHR) data mining. Major efforts will be devoted to:
- Harmonizing established biomarker assays (e.g., HbA1c, c-peptide) using metrology-based reference methods and materials.
- Identifying and validating additional biomarkers for T1D prevention, diagnosis, and management, ensuring rigorous validation and reproducibility across laboratories.
